Skip to content

Public FDA record

Z-1304-2023: ACL ELITE- Analyzer designed specifically for clinical use in the hemostasis laboratory, for coagulation

Recall record Z-1304-2023 for Instrumentation Laboratory. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1304-2023
Company in FDA record
Instrumentation Laboratory
FDA classification date
Sep 30, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Removes the test definition for HemosIL Liquid Anti-Xa (PN 0020302600 and 0020302601) from the ACL Elite/Elite Pro instruments

Source facts

Action
Werfen issued UPDATED- URGENT MEDICAL DEVICE REMOVAL MANDATORY TEST LIBRARY UPGRADE to 02.05.00 ACL ELITE/ ELITE PRO HEMOSTASIS TESTING SYSTEMS dated 2/3/23. {This is a follow up to the original notification that advised your facility of the removal of HemosIL Liquid Anti-Xa assay (PN 0020302600/0020302601) on the ACL Elite/Elite Pro system.} Letter states reason for recall, and action to take: The 02.05.00 Mandatory Library release can be installed on ACL Elite/Elite Pro systems, currently running software version 04.00.00 or 03.01.04, with Library 02.03.00 or higher. Any ACL Elite/Elite Pro system running a Test Library prior to 02.03.00 will first require an upgrade to ACL Elite/Elite Pro software 04.00.00 or 03.01.04, with Test Library 02.03.00, before upgrading to Test Library 02.05.00. Your local Werfen representative will install the 02.05.00 Mandatory Test Library at your next scheduled preventative maintenance or service applications visit. If you have any questions or require further assistance, please contact your local representative, or for technical questions, contact Werfen Technical Support Center at 1-800-678-0710, Option # 1 (English), Option # 1 (ACL Hemostasis Products). As part of this same final corrective action phase, test parameters on the ACL TOP Family/ACL TOP Family 50 Series will be released in later Q2 2023, with reduced on-board instrument claims to 4 days. The updates to remove the assay from the ACL Elite/Elite Pro and reduce the on-board instrument stability claims for the ACL TOP Family/ACL TOP Family 50 Series to 4 days is consistent with the FDA clearance under Special 510(k) K213464
Initiated
2023-02-03
Root cause
Device Design
Distribution
Worldwide distribution - US Nationwide and the countries of Canada, Albania, Algeria, Australia, Austria, Azerbaijan, Belarus, Belgium, Brazil, Bulgaria, Cape Verde, China, Colombia, Czech Republic, Egypt, Falkland Islands, Finland, France, Georgia, Germany, Ghana, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Ireland, Italy, Japan, Jordan, Kazakhstan, Kenya, Kossovo, Latvia, Lebanon, Lithuania, Malawi, Malaysia, Mexico, Philippines, Poland, Romania, Russian Fed., Saudi Arabia, Serbia, South Africa, South Korea, Spain, Sri Lanka, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, Uruguay, Utd.Arab Emir., Vietnam, Zimbabwe.
Recall number
Z-1304-2023
Recall status
Open, Classified
CDRH record ID
198748
FDA classified
2024-09-30
Recall event number
91748

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗